|
FI2911699T4
(fi)
*
|
2012-10-23 |
2025-12-09 |
Synaffix Bv |
Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
|
|
MX379256B
(es)
*
|
2013-03-15 |
2025-03-10 |
Regeneron Pharma |
Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
|
|
PL2991683T3
(pl)
*
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
KR102252925B1
(ko)
|
2013-08-26 |
2021-05-18 |
리제너론 파마슈티칼스 인코포레이티드 |
마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
|
|
EP3058083B1
(en)
*
|
2013-10-14 |
2018-04-11 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057066A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP2935608A1
(en)
|
2013-10-14 |
2015-10-28 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
JP6564369B2
(ja)
|
2013-12-09 |
2019-08-21 |
デュレクト コーポレイション |
薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
|
|
CN106660967A
(zh)
|
2014-01-24 |
2017-05-10 |
西纳福克斯股份有限公司 |
(杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
|
|
WO2015112016A1
(en)
*
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
CA2944539A1
(en)
|
2014-04-08 |
2015-10-15 |
University Of Georgia Research Foundation, Inc. |
Site-specific antibody-drug glycoconjugates and methods
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
EP2974744A1
(en)
|
2014-07-16 |
2016-01-20 |
Stichting Katholieke Universiteit |
Strain-promoted oxidation controlled cycloaddition with high reaction rate
|
|
EP3177633B1
(en)
|
2014-08-04 |
2022-07-20 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
WO2016053107A1
(en)
*
|
2014-10-03 |
2016-04-07 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
WO2016090157A1
(en)
*
|
2014-12-04 |
2016-06-09 |
Celgene Corporation |
Biomolecule conjugates
|
|
WO2016109802A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Development Center For Biotechnology |
Site-specific conjugation through glycoproteins linkage and method thereof
|
|
US11559581B2
(en)
*
|
2015-01-09 |
2023-01-24 |
Oxford University Innovation Limited |
Antibody conjugates and methods of making the antibody conjugates
|
|
EA034950B1
(ru)
|
2015-03-27 |
2020-04-09 |
Регенерон Фармасьютикалз, Инк. |
Производные майтанзиноида, их конъюгаты и способы использования
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
WO2016172615A1
(en)
*
|
2015-04-24 |
2016-10-27 |
University Of Delaware |
Synthetic n-acetyl-muramic acid derivatives and uses thereof
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
WO2017032888A1
(en)
*
|
2015-08-26 |
2017-03-02 |
Vib Vzw |
Means and methods for monitoring inflammation
|
|
KR20180058737A
(ko)
*
|
2015-10-07 |
2018-06-01 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
|
|
JP6486316B2
(ja)
|
2015-11-03 |
2019-03-20 |
財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
|
|
JP2018536682A
(ja)
|
2015-12-11 |
2018-12-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
|
|
WO2017132173A1
(en)
*
|
2016-01-25 |
2017-08-03 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
CN108495653A
(zh)
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
|
WO2017137423A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Improved sulfamide linkers for use in bioconjugates
|
|
JP2017200902A
(ja)
*
|
2016-02-08 |
2017-11-09 |
シンアフィックス ビー．ブイ． |
Ｈｅｒ２腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
CN109069658B
(zh)
*
|
2016-02-08 |
2022-10-14 |
西纳福克斯股份有限公司 |
用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法
|
|
WO2017137457A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
EP3413916A1
(en)
*
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
US10858641B2
(en)
|
2016-02-08 |
2020-12-08 |
Synaffix B.V. |
Enzymes for trimming of glycoproteins
|
|
CN109152844B
(zh)
|
2016-02-08 |
2022-11-22 |
西纳福克斯股份有限公司 |
用于治疗的含有磺酰胺接头的生物缀合物
|
|
JP2017197512A
(ja)
*
|
2016-02-08 |
2017-11-02 |
シンアフィックス ビー．ブイ． |
Ｃｄ３０腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
EP3423105B1
(en)
|
2016-03-02 |
2021-05-05 |
Eisai R&D Management Co., Ltd. |
Eribulin-based antibody-drug conjugates and methods of use
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
JP7020403B2
(ja)
|
2016-05-02 |
2022-02-16 |
味の素株式会社 |
アジド基含有Ｆｃタンパク質
|
|
US12071487B2
(en)
*
|
2016-06-17 |
2024-08-27 |
Life Technologies Corporation |
Site-specific crosslinking of antibodies
|
|
WO2018002016A1
(en)
|
2016-06-28 |
2018-01-04 |
Ventana Medical Systems, Inc. |
Application of click chemistry for signal amplification in ihc and ish assays
|
|
WO2018002902A1
(en)
|
2016-07-01 |
2018-01-04 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
|
EP4159749A3
(en)
*
|
2016-07-01 |
2023-06-14 |
Daiichi Sankyo Company, Limited |
A method for producing fc-containing molecule with remodeled sugar chain
|
|
MX2019003325A
(es)
*
|
2016-09-23 |
2019-08-05 |
Regeneron Pharma |
Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
KR20250114431A
(ko)
|
2016-11-08 |
2025-07-29 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
US11135306B2
(en)
*
|
2016-11-14 |
2021-10-05 |
CHO Pharma Inc. |
Antibody-drug conjugates
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
WO2018126092A1
(en)
*
|
2016-12-29 |
2018-07-05 |
Development Center For Biotechnology |
Processes for preparing glycoprotein-drug conjugates
|
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
JP2020507584A
(ja)
|
2017-02-10 |
2020-03-12 |
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ |
癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート
|
|
WO2018206734A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
|
WO2018213082A1
(en)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
|
|
KR20250008984A
(ko)
|
2017-05-18 |
2025-01-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
FI3635009T3
(fi)
|
2017-06-07 |
2026-04-07 |
Regeneron Pharma |
Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
|
|
WO2019030284A1
(en)
|
2017-08-09 |
2019-02-14 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF
|
|
ES2803350T3
(es)
*
|
2017-08-11 |
2021-01-26 |
Life Science Inkubator Sachsen Gmbh & Co Kg |
Novedosos conjugados de anticuerpos adecuados para su uso en inmunoensayos aislados de desplazamiento de la inactivación de la fluorescencia
|
|
IL301637B2
(en)
*
|
2017-09-29 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
MX2020004691A
(es)
|
2017-11-07 |
2020-08-20 |
Regeneron Pharma |
Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
|
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
|
EP3720504A1
(en)
*
|
2017-12-06 |
2020-10-14 |
Synaffix B.V. |
Enediyne conjugates
|
|
CN111566117A
(zh)
|
2017-12-29 |
2020-08-21 |
糖模拟物有限公司 |
E-选择蛋白和半乳凝素-3的异双功能抑制剂
|
|
CN112004557B
(zh)
|
2018-01-08 |
2024-07-30 |
里珍纳龙药品有限公司 |
类固醇类化合物及其抗体偶联物
|
|
MX2020011487A
(es)
|
2018-04-30 |
2020-12-07 |
Regeneron Pharma |
Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
|
|
CN112533951A
(zh)
|
2018-05-09 |
2021-03-19 |
里珍纳龙药品有限公司 |
抗msr1抗体及其使用方法
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
JP2019206491A
(ja)
*
|
2018-05-29 |
2019-12-05 |
国立研究開発法人理化学研究所 |
乳がんまたは胃がんの治療のための抗体−薬物複合体
|
|
JP7273858B2
(ja)
*
|
2018-06-15 |
2023-05-15 |
シャンハイ ミラコーケン インコーポレイティド |
癌を治療するための方法と材料
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP7576542B2
(ja)
*
|
2018-08-02 |
2024-10-31 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびそれらの使用
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
IL321905A
(en)
*
|
2018-08-02 |
2025-09-01 |
Dyne Therapeutics Inc |
Muscle-targeted conjugates and their uses in the treatment of myotonia dystrophica
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US20220193250A1
(en)
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
EP3829595A4
(en)
|
2018-08-02 |
2022-08-24 |
Dyne Therapeutics, Inc. |
MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
|
|
CN113260384A
(zh)
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
|
MA53455B1
(fr)
|
2018-11-20 |
2022-11-30 |
Regeneron Pharma |
Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr
|
|
MA53765B2
(fr)
|
2018-12-21 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Tubulysines et conjugués tubulysines-protéines
|
|
JP7591503B2
(ja)
|
2018-12-21 |
2024-11-28 |
リジェネロン ファーマシューティカルズ，インク． |
リファマイシンアナログおよびその抗体薬物コンジュゲート
|
|
CN118373810A
(zh)
|
2018-12-27 |
2024-07-23 |
糖模拟物有限公司 |
抑制c-糖苷的半乳凝素-3
|
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
|
EP3908323A2
(en)
|
2019-01-08 |
2021-11-17 |
Regeneron Pharmaceuticals, Inc. |
Traceless linkers and protein-conjugates thereof
|
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
|
US20220040319A1
(en)
|
2019-02-21 |
2022-02-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
|
AU2020246448A1
(en)
*
|
2019-03-25 |
2021-10-14 |
Daiichi Sankyo Company, Limited |
Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
EP3950061A4
(en)
*
|
2019-03-25 |
2022-11-16 |
Daiichi Sankyo Company, Limited |
ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
|
|
TWI841715B
(zh)
*
|
2019-03-27 |
2024-05-11 |
日商第一三共股份有限公司 |
抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
|
|
EP3976112A1
(en)
|
2019-06-03 |
2022-04-06 |
Synaffix B.V. |
Acetal-based cleavable linkers
|
|
US11896682B2
(en)
|
2019-09-16 |
2024-02-13 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
|
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
|
JP7252333B2
(ja)
*
|
2019-09-29 |
2023-04-04 |
煙台邁百瑞国際生物医薬股▲ふん▼有限公司 |
酸法による抗体薬物複合体中間体の調製方法及びその応用
|
|
GB201917388D0
(en)
*
|
2019-11-28 |
2020-01-15 |
Cambridge Entpr Ltd |
Novel linker compounds
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
IL294321B1
(en)
*
|
2020-01-09 |
2026-04-01 |
Mersana Therapeutics Inc |
Antibody-drug conjugates are attached at a specific site with linkers that include peptides.
|
|
CN115768483A
(zh)
*
|
2020-01-13 |
2023-03-07 |
西纳福克斯股份有限公司 |
抗体与免疫细胞衔接器的缀合物
|
|
CN115666656A
(zh)
|
2020-01-13 |
2023-01-31 |
西纳福克斯股份有限公司 |
通过环加成双侧功能化抗体
|
|
WO2021144314A1
(en)
|
2020-01-13 |
2021-07-22 |
Synaffix B.V. |
Via cycloaddition bilaterally functionalized antibodies
|
|
AU2021210987A1
(en)
|
2020-01-24 |
2022-08-04 |
Regeneron Pharmaceuticals, Inc. |
Protein-antiviral compound conjugates
|
|
IL295312A
(en)
|
2020-02-28 |
2022-10-01 |
Regeneron Pharma |
Bispecific antigen binding molecules that bind her2, and methods of use thereof
|
|
IL319200A
(en)
|
2020-04-16 |
2025-04-01 |
Regeneron Pharma |
Antibody-drug conjugates prepared using Diels-Alder compression methods
|
|
WO2021231798A1
(en)
|
2020-05-13 |
2021-11-18 |
Disc Medicine, Inc. |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
EP4159235A4
(en)
|
2020-05-25 |
2024-07-10 |
Foundation for Biomedical Research and Innovation at Kobe |
PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE
|
|
CN111560078A
(zh)
*
|
2020-06-19 |
2020-08-21 |
联宁（苏州）生物制药有限公司 |
具有马来酰亚胺接头的双臂中间体及其合成方法
|
|
JP2023533218A
(ja)
|
2020-06-24 |
2023-08-02 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ツブリシン及びタンパク質－ツブリシンコンジュゲート
|
|
WO2021260232A1
(en)
|
2020-06-26 |
2021-12-30 |
Synaffix B.V. |
Methods for the preparation of linker payload constructs
|
|
KR20240038138A
(ko)
|
2020-07-13 |
2024-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
|
NL2026400B1
(en)
*
|
2020-09-02 |
2022-05-04 |
Synaffix Bv |
Methods for the preparation of bioconjugates
|
|
CA3191304A1
(en)
|
2020-09-14 |
2022-03-17 |
Amy Han |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
WO2022058395A1
(en)
|
2020-09-15 |
2022-03-24 |
Synaffix B.V. |
Antibody-exatecan conjugates
|
|
CA3195303A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Gerardus Josephus BOONS |
Glycoconjugates
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
AU2021366691B2
(en)
|
2020-10-22 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies and methods of use thereof
|
|
NL2026947B1
(en)
|
2020-11-20 |
2022-07-01 |
Synaffix Bv |
Tyrosine-based antibody conjugates
|
|
WO2022136705A1
(en)
|
2020-12-24 |
2022-06-30 |
Synaffix B.V. |
Glycan-conjugated antibodies binding to fc-gamma receptor
|
|
US20240117356A1
(en)
|
2020-12-31 |
2024-04-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN117157107A
(zh)
|
2021-02-08 |
2023-12-01 |
西纳福克斯股份有限公司 |
多功能抗体
|
|
JP7717832B2
(ja)
|
2021-04-10 |
2025-08-04 |
ジェンマブ エー／エス |
Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
|
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
IL309936A
(en)
|
2021-07-09 |
2024-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of dystrophinopathy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
MX2024000897A
(es)
|
2021-07-28 |
2024-02-06 |
Regeneron Pharma |
Conjugados de proteina y compuestos antivirales.
|
|
CN118119633A
(zh)
*
|
2021-10-20 |
2024-05-31 |
岩唐生物科技(杭州)有限责任公司 |
位点特异性糖蛋白偶联物及其制备方法
|
|
KR102782629B1
(ko)
*
|
2021-11-12 |
2025-03-19 |
닥터아이앤비(주) |
생산 시간을 단축하고 안정성이 개선된 의약품 제조방법
|
|
JP2024540480A
(ja)
|
2021-11-17 |
2024-10-31 |
ディスク・メディシン・インコーポレイテッド |
腎臓疾患の貧血を処置する方法
|
|
US20230414775A1
(en)
|
2021-12-29 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
CA3241734A1
(en)
|
2022-01-12 |
2023-07-20 |
Amy Han |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
|
JP2025503700A
(ja)
|
2022-01-14 |
2025-02-04 |
レジェネロン ファーマシューティカルズ， インコーポレイテッド |
ベルカリンａ誘導体及びその抗体薬物複合体
|
|
CN118541380A
(zh)
*
|
2022-01-27 |
2024-08-23 |
岩唐生物科技(杭州)有限责任公司 |
具有多种载荷的蛋白偶联物及其制备方法
|
|
AU2023223557A1
(en)
|
2022-02-22 |
2024-10-03 |
Adc Therapeutics Sa |
Conjugation method involving a transglutaminase at the fc region comprising a trimmed n-glycan
|
|
AU2023231305A1
(en)
|
2022-03-11 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof
|
|
IL315366A
(en)
|
2022-03-23 |
2024-11-01 |
Synaffix Bv |
Antibody pairs for targeting PTK7-expressing tumors
|
|
IL315205A
(en)
|
2022-03-23 |
2024-10-01 |
Synaffix Bv |
Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
|
|
EP4496593A1
(en)
|
2022-03-23 |
2025-01-29 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing nectin-4
|
|
KR20250024743A
(ko)
|
2022-03-23 |
2025-02-19 |
시나픽스 비.브이. |
Trop-2를 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
|
|
US20250339553A1
(en)
|
2022-04-15 |
2025-11-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
EP4285934A1
(en)
|
2022-05-30 |
2023-12-06 |
CER Groupe |
Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
|
|
CA3261366A1
(en)
|
2022-07-21 |
2024-01-25 |
Firefly Bio, Inc. |
GLUCOCORTICOID RECEPTOR AGONISTS AND THEIR CONJUGATES
|
|
EP4572798A1
(en)
|
2022-08-15 |
2025-06-25 |
Synaffix B.V. |
Anthracyclins and conjugates thereof
|
|
EP4344707A1
(en)
|
2022-09-29 |
2024-04-03 |
Emergence Therapeutics AG |
New anti-nectin-4 antibody drug conjugates
|
|
CN120659785A
(zh)
|
2022-11-30 |
2025-09-16 |
里珍纳龙药品有限公司 |
Tlr7激动剂及其抗体-药物缀合物
|
|
WO2024121123A1
(en)
|
2022-12-06 |
2024-06-13 |
Synaffix B.V. |
Synthesis of endo-bicyclononene
|
|
IL321285A
(en)
|
2022-12-21 |
2025-08-01 |
Regeneron Pharma |
Topoisomerase I inhibitor prodrugs for ADC conjugates and a regimen for their use
|
|
EP4637835A1
(en)
*
|
2022-12-22 |
2025-10-29 |
Janssen Pharmaceutica NV |
Methods of preparing antibody-polynucleotide conjugates
|
|
EP4389152A1
(en)
|
2022-12-23 |
2024-06-26 |
Synaffix B.V. |
Conjugates of pbd prodrugs
|
|
WO2024150074A2
(en)
|
2023-01-13 |
2024-07-18 |
Takeda Pharmaceutical Company Limited |
Coronavirus antibodies and therapeutic uses thereof
|
|
TW202434309A
(zh)
|
2023-01-19 |
2024-09-01 |
大陸商上海盛迪醫藥有限公司 |
酪胺酸酶介導的蛋白定點偶聯及其應用
|
|
EP4410313A1
(en)
|
2023-01-31 |
2024-08-07 |
Synaffix B.V. |
Homogeneous antibody-conjugates with high payload loading
|
|
EP4661914A1
(en)
|
2023-02-09 |
2025-12-17 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates via inverse electron demand diels-alder reactions
|
|
EP4673469A1
(en)
|
2023-03-02 |
2026-01-07 |
Alloy Therapeutics, Inc. |
Anti-cd22 antibodies and uses thereof
|
|
WO2024199432A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Site-speicfic orthogonal bioconjugate modality and application thereof
|
|
CN121002057A
(zh)
*
|
2023-03-30 |
2025-11-21 |
启德医药科技（苏州）有限公司 |
二糖接头、含有该二糖接头的接头-有效载荷以及聚糖链重构的抗体-药物偶联物及其制备方法和用途
|
|
EP4450093A1
(en)
|
2023-04-17 |
2024-10-23 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
CN121219014A
(zh)
|
2023-04-17 |
2025-12-26 |
西纳福克斯股份有限公司 |
可切割的免疫细胞接合器
|
|
EP4450489A1
(en)
|
2023-04-18 |
2024-10-23 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
EP4705343A1
(en)
|
2023-05-02 |
2026-03-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
AU2024267410A1
(en)
|
2023-05-08 |
2026-01-08 |
Sanofi |
Glycosylation of immunoglobulin single variable domains
|
|
WO2024251826A1
(en)
|
2023-06-05 |
2024-12-12 |
Vib Vzw |
Glyco-engineered antibody-drug-conjugates comprising an oxime linker
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
KR20260039735A
(ko)
*
|
2023-07-10 |
2026-03-20 |
수리오 테라퓨틱스 컴퍼니 리미티드 |
기능화된 아우리스타틴, 약제학적 조성물, 및 치료적 적용
|
|
AU2024299328A1
(en)
|
2023-07-21 |
2026-01-22 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
AU2024353316A1
(en)
|
2023-09-26 |
2026-03-26 |
Genmab A/S |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
EP4541376A1
(en)
|
2023-10-17 |
2025-04-23 |
ADC Therapeutics SA |
Antibody-drug conjugates
|
|
US20250171516A1
(en)
|
2023-11-03 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
EP4574174A1
(en)
|
2023-12-19 |
2025-06-25 |
Jack Elands |
Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025163120A1
(en)
|
2024-02-01 |
2025-08-07 |
Adcytherix Sas |
ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
|
|
WO2025172468A1
(en)
|
2024-02-13 |
2025-08-21 |
Synaffix B.V. |
Method for producing azido-sugars and compounds obtained thereby
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025238253A1
(en)
|
2024-05-16 |
2025-11-20 |
Synaffix B.V. |
Antibody-oligonucleotide conjugates
|
|
WO2025262641A1
(en)
|
2024-06-19 |
2025-12-26 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006494A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-cd3 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026008881A1
(en)
|
2024-07-05 |
2026-01-08 |
Synaffix B.V. |
Extracellular vesicles comprising biomolecule-conjugates
|
|
WO2026020031A2
(en)
|
2024-07-18 |
2026-01-22 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|
|
WO2026035986A1
(en)
|
2024-08-07 |
2026-02-12 |
Bighat Biosciences, Inc. |
Humanized anti-cdh17 antibodies and use of the same
|
|
WO2026039642A1
(en)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Anti-mesothelin antibody conjugates and methods of use thereof
|
|
WO2026052513A1
(en)
|
2024-09-09 |
2026-03-12 |
Adcytherix Sas |
Antibody-drug conjugates comprising an flt3 binding antibody
|